OCC - Orthocell raising $3.5 million; adds heavy hitters to register
(NewsDirect)
Orthocell Ltd(ASX:OCC) managing director Paul Anderson sits down with JonathanJackson in the Proactive studio to discuss the company’s $3.5million capital raise and the addition of some heavy hitting investorsto the share register. The company is now cashed up to pursue itsglobal market strategy of advancing its Striate+ bone repair andRemplir nerve repair products in international markets. The company isfocused on a strategic regulatory program and the completion of apivotal nerve repair study for US regulatory approval in 2024. It hasalso has also solidified a long-term partnership with the Universityof Western Australia.
Orthocell chair John Van Der Wielen said: “The support ofthese strategic investors is an endorsement of Orthocell’s science,business strategy and progress in commercialising its leading bone andnerve repair products, and the exciting outlook for the company as itprogresses approvals in new key jurisdictions like theUS."
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.